SummaryRMgm-172
|
Successful modification | The parasite was generated by the genetic modification |
The mutant contains the following genetic modification(s) | Gene disruption |
Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 18466298 Reference 2 (PMID number) : 21299648 |
MR4 number | |
top of page | |
Parent parasite used to introduce the genetic modification | |
Rodent Malaria Parasite | P. yoelii |
Parent strain/line | P. y. yoelii 17XNL |
Name parent line/clone | clone 1.1 |
Other information parent line | 17XNL is a non-lethal strain of P. yoelii |
top of page | |
The mutant parasite was generated by | |
Name PI/Researcher | A.S.I. Aly; S.H.I. Kappe |
Name Group/Department | Seattle Biomedical Research Institute |
Name Institute | Not applicable |
City | Seattle |
Country | USA |
top of page | |
Name of the mutant parasite | |
RMgm number | RMgm-172 |
Principal name | sap1(-) |
Alternative name | |
Standardized name | |
Is the mutant parasite cloned after genetic modification | Yes |
top of page | |
Phenotype | |
Asexual blood stage | Not different from wild type |
Gametocyte/Gamete | Not different from wild type |
Fertilization and ookinete | Not different from wild type |
Oocyst | Not different from wild type |
Sporozoite | Normal numbers of salivary gland sporozoites are formed. Sporozoites lack sap1 transcripts. Infection of mice by mosquito bite or by inoculation of salivary gland sporozoites did not result in a blood stage infection. Sporozoites show normal gliding, hepatocyte traversal and invasion in vitro. |
Liver stage | Infection of mice by mosquito bite or by inoculation of salivary gland sporozoites did not result in a blood stage infection. Sporozoites show normal gliding, hepatocyte traversal and invasion in vitro. In vitro in HepG2-CD81 cells the number of developing liver stages gradually decrease between 6 and 12h after infection and sharply decrease between 18 and 24h after infection. In addition, the liver stages failed to growth and develop. |
Additional remarks phenotype | Mutant/mutation Protein (function) Additional information By IFA analysis using antibodies against SAP1 a specific sporozoite-internal staining was observed that excluded the nucleus and was distinct from circumsporozoite (CS) protein staining, suggesting a cytoplasmic location. |
top of page | |||||||||||||||||||||||||
Details of the target gene | |||||||||||||||||||||||||
Gene Model of Rodent Parasite | PY17X_0903500 | ||||||||||||||||||||||||
Gene Model P. falciparum ortholog | PF3D7_1147000 | ||||||||||||||||||||||||
Gene product | sporozoite and liver stage asparagine-rich protein | sporozoite asparagine-rich protein | ||||||||||||||||||||||||
Gene product: Alternative name | SAP1, SLARP; sporozoite (and liver stage) asparagine-rich protein; S22 | ||||||||||||||||||||||||
top of page | |||||||||||||||||||||||||
Details of the genetic modification | |||||||||||||||||||||||||
Inducable system used | No | ||||||||||||||||||||||||
Additional remarks inducable system | |||||||||||||||||||||||||
Type of plasmid/construct used | Plasmid double cross-over | ||||||||||||||||||||||||
PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||||||||
Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||
Plasmid/construct map | |||||||||||||||||||||||||
Plasmid/construct sequence | |||||||||||||||||||||||||
Restriction sites to linearize plasmid | KpnI/SacII | ||||||||||||||||||||||||
Partial or complete disruption of the gene | Partial | ||||||||||||||||||||||||
Additional remarks partial/complete disruption | Part of the 3' coding sequence of the gene remained in the genome after the disruption event (see figure 3.A: A.S.I. Aly et al., Mol Microbiol, 2008, 69: 152-163). | ||||||||||||||||||||||||
Selectable marker used to select the mutant parasite | tgdhfr | ||||||||||||||||||||||||
Promoter of the selectable marker | pbdhfr | ||||||||||||||||||||||||
Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||
Selection (negative) procedure | No | ||||||||||||||||||||||||
Additional remarks genetic modification | |||||||||||||||||||||||||
Additional remarks selection procedure | |||||||||||||||||||||||||
Primer information: Primers used for amplification of the target sequences
Primer information: Primers used for amplification of the target sequences
| |||||||||||||||||||||||||
top of page |